| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
LD-110 (1-10 μM) has a linker group containing four methylene groups and exhibits good degradation activity. At concentrations of 1, 3 and 10 μM, the degradation rates of LSD1 protein are 65%, 70% and 84%, respectively [1]. LD-110 (0.39-12.5 μM) has a strong binding affinity for LSD1 (Kd = 6.2 μM) [1]. LD-110 (0.1-30 μM, 6-72 hours) can effectively and dose-dependently degrade LSD1 protein, and almost completely degrade it within 48-72 hours. The DC50 values in KYSE-150, KYSE-30 and EC9706 esophageal squamous cell carcinoma (ESCC) cells are 0.44, 1.18 and 1.24 μM, respectively. This degradation is highly specific and has minimal effect on CoREST/HDAC1/HDAC2 levels, thus leading to a significant accumulation of H3K4me2 by 2 to 7 times [1]. In KYSE-150 esophageal squamous cell carcinoma cells, LD-110 (3 μM, 42 h) induced LSD1 degradation that could be effectively blocked by LSD1 inhibitors (LI-1), cereblon E3 ligand (Thalidomide), NAE inhibitors (MLN4924), and proteasome inhibitors (MG132) [1]. LD-110 (72 h) effectively inhibited the growth of esophageal squamous cell carcinoma (ESCC) cells, with half-maximal inhibitory concentrations (IC50) of 3.94, 3.35, and 3.08 μM in KYSE-150, KYSE-30, and EC9706 cells, respectively [1]. LD-110 (3-10 μM, 10-14 days) effectively inhibited the proliferation of esophageal squamous cell carcinoma lines KYSE-30 and EC9706[1]. LD-110 (3-10 μM, 48 hours) induced early and late apoptosis in KYSE-30 and EC9706 cells in a dose-dependent manner and caused lysis of PARP and caspase-3[1].
|
|---|---|
| ln Vivo |
LD-110 (30 mg/kg, 100 mg/kg, intraperitoneal injection, once daily for 24 days) showed potent dose-suggested antitumor activity in the KYSE-150 xenograft model without causing significant toxicity [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: KYSE-150, KYSE-30, and EC9706 ESCC cells Tested Concentrations: 10 μM Incubation Duration: 6 h, 12 h, 24 h, 48 h, 72 h Experimental Results: Effectively reduced the LSD1 protein levels after 24-48 h treatment, achieving near-complete depletion of LSD1 at 48−72 h, consequently causing the accumulation of H3K4me2. Western Blot Analysis[1] Cell Types: KYSE-150, KYSE-30, and EC9706 ESCC cells Tested Concentrations: 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM Incubation Duration: 48 h Experimental Results: Caused the dose-dependent degradation of LSD1 with DC50 values of 0.44, 1.18, and 1.24 μM in the KYSE-150, KYSE-30, and EC9706, respectively. Caused accumulation of H3K4me2, which also occurred in a dose-dependent manner. Cell Proliferation Assay[1] Cell Types: KYSE-30, EC9706 ESCC cells Tested Concentrations: 3 μM, 10 μM Incubation Duration: 10-14 days Experimental Results: Significantly reduced the number of clones formed in ESCC KYSE-30 and EC9706 cells in a dose-dependent manner. Apoptosis Analysis[1] Cell Types: KYSE-30 cells, EC9706 ESCC cells Tested Concentrations: 3 μM, 10 μM Incubation Duration: 48 h Experimental Results: Induced both early-stage and late-stage apoptosis in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: 5 × 106 KYSE-150 cells were injected into both flanks of the male BALB/c nude mice[1].
Doses: 30 mg/kg, 100 mg/kg Route of Administration: I.p., once daily for 24 days Experimental Results: Dose-dependently inhibited the tumor growth at both 30 and 100 mg/ kg via intraperitoneal administration without any effect on body weight. At a dose of 100 mg/kg also effectively reduced the levels of LSD1 protein in the tumor tissues harvested and collected at the end of the study without causing any morphological changes of major organs, including heart, liver, spleen, lung, and kidney. |
| References |
| Molecular Formula |
C42H41N7O6
|
|---|---|
| Molecular Weight |
739.82
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3517 mL | 6.7584 mL | 13.5168 mL | |
| 5 mM | 0.2703 mL | 1.3517 mL | 2.7034 mL | |
| 10 mM | 0.1352 mL | 0.6758 mL | 1.3517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
